The synchrony between the regulatory system and intellectual property is complex and often contradictory.
While many Latin American countries have a relatively robust and well-developed intellectual property system, it is also plagued by a number of significant deficiencies. For example, the fact that the regulatory system in many cases is inadequate in terms of enforcement of IP rights , which often leads to situations of infringement and unfair competition, since companies that enjoy a financially well-off could afford to infringe intellectual property rights without fear of repercussions from patent holders.
The "synchrony" refers to a coincidence of events at a certain time, this is how, applied to regulatory and intellectual property systems, it is an adequate word that should describe the relationship between both systems. The Regulatory System, as in charge of managing the regulatory authorization for the marketing of new medicines in each country, must be synchronized with the protection of intellectual property rights, in particular, with patent rights, so that in this way there is an effective protection of the intellectual assets related to a medicine, and at the same time, a reasonable and expeditious access to generic medicines is guaranteed. Read more